Weight-Adjusted Thromboprophylaxis Dosing in Hospitalized Cancer Patients

Weight-adjusted dosing of the anticoagulant enoxaparin was safe when compared with standard fixed dosing in a phase II study.

Anticoagulants are advised for prophylaxis and treatment of selected ambulatory cancer patients and those with confirmed venous thromboembolism (VTE). Despite a common association between VTE and recent hospitalization, best practices regarding VTE prophylaxis in hospitalized cancer patients are unknown.

To address this issue, investigators conducted a multicenter, double-blind, randomized, controlled, phase II trial comparing fixed dosing of the low-molecular-weight heparin enoxaparin (40 mg daily) versus weight-adjusted dosing of the agent (1 mg/kg) for up to 14 days in 47 evaluable cancer inpatients at high risk for VTE based on Padua score. Clinical assessments were conducted at day 14. Patients who received fixed-dose enoxaparin underwe…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Weight-Adjusted Thromboprophylaxis Dosing in Hospitalized Cancer Patients

Topics

Reviewing Author